person · Reporting owner

PERRY MARK L

Disclosed activity across 4 companies

Tapewire entity: 11385
SEC CIK: 0001190270

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	EVP Operations	February 03, 2004	February 04, 2004

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date February 03, 2004 · Filed February 04, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	203,772	Reported balance After 2004-02-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2004-02-03 · Exercise / conversion · Acquired 9,716 · Balance 203,772
Common StockSEC Table I · non-derivative	Direct	243,772	Reported balance After 2004-02-03 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2004-02-03 · Exercise / conversion · Acquired 40,000 · Balance 243,772
Common StockSEC Table I · non-derivative	Direct	246,056	Reported balance After 2004-02-03 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2004-02-03 · Exercise / conversion · Acquired 2,284 · Balance 246,056
Common StockSEC Table I · non-derivative	Direct	238,556	Reported balance After 2004-02-03 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2004-02-03 · Sale · Disposed 7,500 · Balance 238,556
Common StockSEC Table I · non-derivative	Direct	226,056	Reported balance After 2004-02-03 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2004-02-03 · Sale · Disposed 12,500 · Balance 226,056
Common StockSEC Table I · non-derivative	Direct	211,056	Reported balance After 2004-02-03 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2004-02-03 · Sale · Disposed 15,000 · Balance 211,056
Common StockSEC Table I · non-derivative	Direct	206,056	Reported balance After 2004-02-03 transaction · row 7 Account or security details depend on footnotes; rows are not merged. 1 source row Row 7 · 2004-02-03 · Sale · Disposed 5,000 · Balance 206,056
Common StockSEC Table I · non-derivative	Direct	201,056	Reported balance After 2004-02-03 transaction · row 8 Account or security details depend on footnotes; rows are not merged. 1 source row Row 8 · 2004-02-03 · Sale · Disposed 5,000 · Balance 201,056
Common StockSEC Table I · non-derivative	Direct	196,340	Reported balance After 2004-02-03 transaction · row 9 Account or security details depend on footnotes; rows are not merged. 1 source row Row 9 · 2004-02-03 · Sale · Disposed 4,716 · Balance 196,340
Common StockSEC Table I · non-derivative	Direct	196,040	Reported balance After 2004-02-03 transaction · row 10 Account or security details depend on footnotes; rows are not merged. 1 source row Row 10 · 2004-02-03 · Gift · Disposed 300 · Balance 196,040 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Common StockSEC Table I · non-derivative	Indirectby Son	5,600	Reported balance After 2004-02-03 transaction · row 11 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 11 · 2004-02-03 · Gift · Acquired 300 · Balance 5,600 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22	Direct	4,568	Reported balance After 2004-02-03 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2004-02-03 · Exercise / conversion · Disposed 2,284 · Balance 4,568 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22	Direct	19,432	Reported balance After 2004-02-03 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2004-02-03 · Exercise / conversion · Disposed 9,716 · Balance 19,432 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2010-04-05	Direct	53,252	Reported balance After 2004-02-03 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2004-02-03 · Exercise / conversion · Disposed 40,000 · Balance 53,252 F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.

Filing footnotes · ownership attribution and instrument terms

F1: Represents transfer of shares to son under Uniform Gift to Minors Act.

F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.

F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.

F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 37,865 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 19, 2020

Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 29,508 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 21,800 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

NVIDIA CORP

Report date June 26, 2024 · Filed June 26, 2024

Section 16 reporting ended · disclosed 2024-06-26. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2020 Filed Jun 12, 2020 22:21 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	712	$0.00	$0.00	Disclosure SEC source: 0001045810-20-000097 · wf-form4_159200048375741.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,735 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 18, 2020 and 50% of the shares on May 19, 2021. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	600	$342.73	$205,636.98	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 14 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,023 F14 · price: Represents weighted average sales price. The shares were sold at prices ranging from $342.40 to $343.35. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	300	$341.54	$102,462.99	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 13 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,623 F13 · price: Represents weighted average sales price. The shares were sold at prices ranging from $341.19 to $341.73. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	300	$340.38	$102,113.01	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 12 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,923 F12 · price: Represents weighted average sales price. The shares were sold at prices ranging from $340.04 to $341.00. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	600	$339.16	$203,494.02	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 11 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,223 F11 · price: Represents weighted average sales price. The shares were sold at prices ranging from $338.65 to $339.61 The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	600	$338.09	$202,855.98	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 10 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,823 F10 · price: Represents weighted average sales price. The shares were sold at prices ranging from $337.57 to $338.51. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	800	$336.97	$269,578.00	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 9 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,423 F9 · price: Represents weighted average sales price. The shares were sold at prices ranging from $336.54 to $337.49. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,202	$335.87	$403,712.13	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 8 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,223 F8 · price: Represents weighted average sales price. The shares were sold at prices ranging from $335.33 to $336.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	404	$333.45	$134,714.37	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 7 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,425 F7 · price: Represents weighted average sales price. The shares were sold at prices ranging from $333.09 to $333.68. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,100	$332.20	$365,420.99	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,829 F6 · price: Represents weighted average sales price. The shares were sold at prices ranging from $331.96 to 332.61. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	2,200	$331.31	$728,885.96	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,929 F5 · price: Represents weighted average sales price. The shares were sold at prices ranging from $330.94 to $331.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,600	$330.32	$528,506.08	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,129 F4 · price: Represents weighted average sales price. The shares were sold at prices ranging from $329.84 to $330.80. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,300	$329.28	$428,062.05	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,729 F3 · price: Represents weighted average sales price. The shares were sold at prices ranging from $328.80 to $329.70. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	802	$327.93	$263,001.70	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,029 F2 · price: Represents weighted average sales price. The shares were sold at prices ranging from $327.68 to $328.28. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 27, 2020 Filed May 29, 2020 22:29 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	400	$326.51	$130,605.00	Disclosure SEC source: 0001045810-20-000077 · wf-form4_159079133647734.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,831 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $326.31 to $326.86. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · derivative · entry 14 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $18.85	$0.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · derivative · entry 13 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	8,600	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · derivative · entry 12 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,600 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · derivative · entry 11 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,295	$79.17	$102,521.65	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 10 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,428 F6 · price: Represents weighted average sales price. The shares were sold at prices ranging from $79.16 to $79.18. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	34,698	$78.65	$2,728,931.77	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 9 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,723 F5 · price: Represents weighted average sales price. The shares were sold at prices ranging from $78.16 to $79.1450. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	13,024	$77.71	$1,012,138.02	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 8 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,421 F4 · price: Represents weighted average sales price. The shares were sold at prices ranging from $77.16 to $78.01. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	600	$76.28	$45,770.52	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 7 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,445 F3 · price: Represents weighted average sales price. The shares were sold at prices ranging from $76.15 to $76.44. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,350	$75.43	$101,833.47	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,045 F2 · price: Represents weighted average sales price. The shares were sold at prices ranging from $75.13 to $75.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	2,633	$74.01	$194,865.17	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,395 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $73.90 to $74.11. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	15,000	$28.45	$426,750.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	15,000	$18.85	$282,750.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	8,600	$20.00	$172,000.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 12, 2020 Filed May 13, 2020 18:07 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	15,000	$20.00	$300,000.00	Disclosure SEC source: 0000899243-20-013017 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	200	$296.89	$59,378.00	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 9 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,231 F9 · price: Represents weighted average sales price. The shares were sold at prices ranging from $296.86 to $296.92. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,459	$296.36	$432,389.24	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 8 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,431 F8 · price: Represents weighted average sales price. The shares were sold at prices ranging from $295.81 to $296.61. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	505	$295.51	$149,232.55	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 7 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,890 F7 · price: Represents weighted average sales price. The shares were sold at prices ranging from $294.80 to $295.79. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	400	$294.19	$117,676.00	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,395 F6 · price: Represents weighted average sales price. The shares were sold at prices ranging from $293.68 to $294.55. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,201	$292.99	$351,880.99	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,795 F5 · price: Represents weighted average sales price. The shares were sold at prices ranging from $292.50 to $293.40. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	615	$291.76	$179,432.40	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,996 F4 · price: Represents weighted average sales price. The shares were sold at prices ranging from $291.38 to $292.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,302	$290.68	$378,465.36	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,611 F3 · price: Represents weighted average sales price. The shares were sold at prices ranging from $290.28 to $291.08. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	2,013	$289.68	$583,125.84	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,913 F2 · price: Represents weighted average sales price. The shares were sold at prices ranging from $289.23 to $290.22. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 18, 2020 Filed Feb 20, 2020 22:59 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	1,057	$288.71	$305,166.47	Disclosure SEC source: 0001045810-20-000024 · wf-form4_158223956728478.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,926 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $288.22 to $289.10. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017617 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $56.30	$0.00	Disclosure SEC source: 0000899243-19-017617 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2019 Filed Jun 17, 2019 19:01 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	2,300	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017232 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2019 Filed Jun 17, 2019 19:01 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	6,600	$0.00 Strike: $47.17	$0.00	Disclosure SEC source: 0000899243-19-017232 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 6,600 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
May 23, 2019 Filed May 28, 2019 22:26 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	1,258	$0.00	$0.00	Disclosure SEC source: 0001045810-19-000099 · wf-form4_155908239758515.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,983 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 20, 2019 and 50% of the shares on May 20, 2020. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:22 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $42.25	$0.00	Disclosure SEC source: 0000899243-18-017769 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
June 12, 2018 Filed Jun 14, 2018 16:06 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $48.85	$0.00	Disclosure SEC source: 0000899243-18-016595 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 12, 2018, such that this option is fully exercisable on June 12, 2019. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
May 17, 2018 Filed May 21, 2018 22:36 UTC	NVIDIA CORP NVDA · Entity 1023	GrantCommon Stock	963	$0.00	$0.00	Disclosure SEC source: 0001045810-18-000071 · wf-form4_152694216041367.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,725 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 21, 2018 and 50% of the shares on May 15, 2019. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document
February 12, 2018 Filed Feb 14, 2018 00:03 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	17,307	$227.93	$3,944,805.28	Disclosure SEC source: 0001045810-18-000006 · wf-form4_151856659697728.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,762 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $227.50 to $228.39. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
August 14, 2017 Filed Aug 16, 2017 20:07 UTC	NVIDIA CORP NVDA · Entity 1023	SaleCommon Stock	16,281	$162.24	$2,641,369.20	Disclosure SEC source: 0001045810-17-000119 · wf-form4_150291402608402.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,069 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $162.18 to $162.42. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 20, 2017 Filed Jun 22, 2017 21:50 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-17-016999 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
June 14, 2017 Filed Jun 16, 2017 16:14 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0000899243-17-016568 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 14, 2017, such that this option is fully exercisable on June 14, 2018. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.